Skip to main content
  • Contact Us
  • Vantage logo Sign Up
  • Subscriber Sign In
Evaluate Logo

navigation

  • What We Do
    • Commercial Intelligence
    • Products
      • Evaluate Pharma
      • Evaluate Omnium
      • Evaluate Medtech
      • Evaluate Epi
      • Japan Drug Forecasts
      • Europe Drug Forecasts
    • Pharma Consulting & Analytics
      • Pharma Consulting & Analytics
      • Data Feeds and APIs
    • Evaluate Vantage
      • News
      • Analysis
      • Policy & Pricing
      • Insights
      • Events
      • Medtech
      • Therapy Areas
      • Editorial Team
      • About Evaluate Vantage
    • Evaluate for Biotech
  • How We Can Help You
    • Pharma and Biotech
    • Financial Services
    • Management Consultancies
    • Service Providers
    • Customer Testimonials
  • Thought Leadership
    • Multimedia
    • Blog
  • About Us
    • Press Releases
    • Media Coverage
    • Executive Team
    • Vision & History
  • Contact Us
  • Sign Up for Evaluate Vantage
  • Talent
  • Subscriber Sign In

 

Vantage logo

Vantage

  • Covid-19
    • Covid-19 Coverage
    • Evaluate Vantage COVID-19 Report
  • News
    • Snippets
    • Deals
    • Trial results
    • Patents and litigation
    • Corporate strategy
  • Analysis
    • Interviews
    • Spotlight
    • Vantage points
    • Vantage views
  • Insights
    • M&A
    • IPO
    • NME approvals
    • Quarterly shareprice performance
    • Venture financing
    • Vantage data points
    • Other data
  • Events
    • Company events
    • Conferences
    • Upcoming events
  • Medtech
  • Therapy Areas
  • About
    • Editorial team

Breadcrumb

  1. Home
  2. Vantage
  3. Topics
  4. Therapeutic Focus
  5. Musculoskeletal

Musculoskeletal

Thumbnail
June 24, 2022

Sarepta loses its Momentum

A clinical hold for the company’s Exondys 51 follow-on adds further pressure on the forthcoming gene therapy readouts.

Thumbnail
June 21, 2022

PTC’s confirmatory Duchenne data resurrect US hopes

Real-world data on Translarna look good, but with a failed confirmatory trial and a troubled history US approval is far from guaranteed.

Article image
Vantage logo
June 14, 2022

A new multiple sclerosis device steps forward

Article image
Vantage logo
June 03, 2022

Eular 2022 – a new IL-17 threatens to underwhelm

Article image
Vantage logo
March 15, 2022

Bridgebio looks to lead limb girdle pipeline

Article image
Vantage logo
March 14, 2022

Bridgebio pushes forward with limb girdle project

Early data are encouraging, but with the biotech market still terrible investors need a lot more to get excited.

Article image
Vantage logo
March 11, 2022

Alvotech settlement completes the list of Humira challengers

Article image
Vantage logo
January 27, 2022

Galvani finally enters the clinic

Article image
Vantage logo
January 11, 2022

JP Morgan 2022 – Sarepta gets another bite at the gene therapy cherry

But unimpressive phase 2 results, plus a lack of a placebo control arm, raise questions.

Article image
Vantage logo
January 10, 2022

JP Morgan 2022 – day one sees healthy deal flow from biopharma

But transactions are small, and mostly involve licensing rather than takeouts, with cancer and gene editing featuring heavily.

Article image
Vantage logo
January 10, 2022

JP Morgan 2022 – Beam and Mammoth hook big pharma partners

Beam signs Pfizer up for $300m up front, while Mammoth’s deal with Bayer is worth a more modest $40m.

  • Load More
We use cookies on this website. By using this site, you agree that we may store and access cookies on your device. Find out more.
Vantage logo
Independent, data-driven daily news and analysis on pharma, biotech and medtech.
Sign up

Latest Reports

June 16, 2022

Vantage Top 10 Most Read Report

June 15, 2022

Asco 2022 eBook

View more...

Editor's Picks

Vantage logo
June 14, 2022

Roche deal fails to Repare the licensing scene

Vantage logo
June 13, 2022

EHA 2022 – Crispr still looks bloody good

Vantage logo
June 05, 2022

Asco 2022 – Enhertu asks, how low can you go?

Vantage logo
June 09, 2022

Asco 2022 movers – cell therapy wins, but it’s not the whole story

Vantage logo
May 30, 2022

Abbvie to become the biggest of pharmas in 2028

Open modal

Evaluate Logo

Evaluate HQ
44-(0)20-7377-0800

Evaluate Americas
+1-617-573-9450

Evaluate APAC
+81-(0)70-4131-0112

Footer menu

  • Terms and conditions
  • Privacy Policies
  • Cookie Policy

© Copyright 2022 Evaluate Ltd.